Monteris Medical Launches NeuroBlate NB3 FullFire 1.6mm Brain Laser Probe

MINNETONKA, Minn., May 1, 2024 – Monteris Medical, a front-runner in image-guided laser interstitial thermal therapy (LITT), has announced the commercial release of the NeuroBlate® NB3™ FullFire® 1.6mm laser probe. This latest innovation in their product line is designed for use with the NeuroBlate System, renowned for its precision in minimally invasive brain surgeries.

The NeuroBlate NB3 laser probe, boasting Monteris Medical's patented cooling technology and the latest advancements in laser fiber technology, is currently the smallest commercially available laser probe for brain applications. Its unique design offers a single adjustable length, providing neurosurgeons with the flexibility to use it in multi-trajectory procedures while ensuring operational convenience. Additionally, the single-probe device enhances economic efficiency for hospitals and simplifies inventory management.

The NB3 laser probe received FDA 510(k) clearance in December 2023 and has been in limited market release since February 2024. Leading institutions across the United States participated in the initial launch phase, utilizing the probe in a variety of procedures, lesion types, sizes, locations, target depths, and patient demographics. Surgeons used the probe for primary tumors, metastatic lesions, radiation necrosis, and epileptogenic foci in both adults and children. The probe successfully ablated lesions ranging from under 10mm to nearly 30mm in diameter, including deep-seated targets and those requiring multiple trajectories.

Engineered for use at power settings between six to 12 watts, the NB3 laser probe can deliver ablations of various sizes, with some physicians experiencing shorter ablation times. This wide range of settings allows for tailored treatment plans to meet specific patient needs.

Monteris Medical will showcase the NB3 laser probe and its advanced thermography capabilities for the NeuroBlate System at the upcoming American Academy of Neurological Surgeons (AANS) annual meeting in Chicago, from May 3-6, 2024. The probe will be featured at Booth 854 in the McCormick Place North Building and highlighted during the AANS "Breakfast Bites" Educational Symposium on May 4 at 7:30 a.m.

Martin J. Emerson, president and CEO of Monteris Medical, expressed his enthusiasm about the launch, stating, "We are excited to introduce the highly anticipated NB3 laser probe to our neurosurgeons and hospital system customers. This product addresses a wide range of patient needs, including pediatric LITT applications. Combined with our NeuroBlate software and robotics, NB3 offers the precision and flexibility demanded by our neurosurgeons. We anticipate that the advanced engineering of NB3 will serve as the foundation for our future probe designs, and our upcoming software releases will provide even more options for our neurosurgeon customers."

Monteris Medical is a privately owned company specializing in the development and marketing of innovative MR-guided ablation systems for minimally invasive, robotically controlled brain surgery. Their NeuroBlate System is the only minimally invasive system with a robotic interface, enabling precise and safe laser energy delivery. The system is designed for ablating intracranial soft tissue, including brain tumors, radiation necrosis, and epileptic foci.

Monteris Medical continues to push the boundaries of medical technology, providing neurosurgeons with cutting-edge tools to improve patient outcomes in brain surgery. With the introduction of the NeuroBlate NB3 laser probe, the company reinforces its commitment to innovation and excellence in the field of neurosurgery.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!